Forigerimod

Summary

Forigerimod (also known as IPP-201101, Lupuzor, P140 peptide) is an investigational phosphopeptide belonging to the immunomodulatory and thymic peptide family. It is being explored as a therapeutic agent for systemic lupus erythematosus (SLE), a chronic autoimmune disease. The compound is classified as an immunomodulatory peptide that inhibits Toll‑like receptor (TLR) signaling pathways. Development is ongoing, and it has not yet received regulatory approval for any indication.

Mechanism of Action

Forigerimod is described as a Toll‑like receptor inhibitor within the immunomodulatory peptide class. By interacting with components of the TLR signaling cascade, it is proposed to dampen innate immune activation that contributes to autoimmunity. This modulation may alter downstream cytokine production and cellular responses, thereby reducing the aberrant immune activity characteristic of systemic lupus erythematosus. Detailed molecular targets and binding interactions have not been disclosed in the available literature.

What the Research Shows

The published literature on Forigerimod is limited to a single 2012 organic chemistry report that details a scalable synthesis of the protected phosphoamino acid building block (Fmoc‑O‑benzyl‑l‑phosphoserine) used to construct the peptide. The article notes that Forigerimod is a phosphopeptide under investigation for systemic lupus erythematosus, but provides no pre‑clinical, clinical, or pharmacological data. Consequently, evidence for its efficacy, safety, or pharmacokinetics remains unavailable beyond the chemical preparation methodology.

Limitations of the Evidence

Evidence for Forigerimod is confined to a synthetic methodology paper; no biological, pre‑clinical, or clinical studies have been reported in the indexed literature. Consequently, its therapeutic potential, optimal dosing, safety profile, and comparative effectiveness remain uncharacterized. The lack of data precludes any assessment of benefit for systemic lupus erythematosus or other conditions.

How It Is Administered

Forigerimod is being investigated for subcutaneous administration. The peptide is formulated for injection, but specific formulation details, dosing regimens, or stability characteristics have not been disclosed in the available sources.

Routes of Administration

Goals & Uses

• Immune modulation without broad immunosuppressionTargeted ImmunotherapyModerate
• Reduction of anti-dsDNA antibodiesBiomarker ModulationModerate
• Steroid-sparing effectCorticosteroid ReductionLow
• Reduction of SLE disease activityAutoimmune/InflammatoryModerate

Contraindications

• Hypersensitivity to forigerimod or excipientsAllergy / HypersensitivityHigh
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Active severe infectionInfectiousHigh

Adverse Effects

• Hypersensitivity reactionsImmunologicRare
• Injection site reactionsLocalCommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• FatigueGeneralUncommonLow energy or tiredness

Drug Interactions

• HydroxychloroquineLow
• CorticosteroidsLow
• Mycophenolate mofetilLow

Population Constraints

• Pediatric patientsAgeRelative
• Severe renal impairment / lupus nephritisOrgan ImpairmentRelative
• Pregnancy and lactationReproductiveRelative

Regulatory Status

• European UnionInvestigationalNot EMA approved. Clinical trials conducted in EU member states. Orphan designation explored.
• United StatesInvestigationalNot FDA approved. Studied under IND in Phase II/III trials for SLE (LUPUZOR, ARISE programs).
• United KingdomInvestigationalNot approved by MHRA. Status mirrors EU investigational classification.

Not approved by FDA, EMA, or other major regulatory agencies as of 2024. Studied under IND/clinical trial frameworks in the US and Europe. Orphan Drug Designation has been explored. Phase IIIARES trial results were mixed.

Evidence & Sources

• A general preparation of protected phosphoamino acids
  Journal ArticleLowPetrillo DE, et al.2012-01-01T00:00:00.000000Z

Frequently Asked Questions